Document:

EX-4.29

 Exhibit 4.29 
 EMPLOYMENT AGREEMENT 
 THIS AGREEMENT made the 1st day of March, 2013

 BETWEEN: 

TEKMIRA PHARMACEUTICALS CORPORATION, a company incorporated under the laws of British Columbia (the “Company”),
with offices at 100 – 8900 Glenlyon Parkway, Burnaby, British Columbia fax: (604) 419-3201 
 AND: 

DIANE GARDINER (the “Executive”), of 
 Surrey, British Columbia 
 WHEREAS: 
 A. The Company is in the business of acquiring, inventing, developing, discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry,
biotechnology and pharmaceuticals; 
 B. The Executive has the expertise, qualifications and required certifications to perform the services
contemplated by this Agreement; and 
 C. The Company wishes to employ the Executive to perform the services, on the terms and conditions herein
set forth, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged. 
 NOW THEREFORE THIS
AGREEMENT WITNESSES that the parties hereto agree as follows: 
  

	1.	EMPLOYMENT 

  

	 	(a)	The Executive will be employed by and will serve the Company as its Vice President, Human Resources. The Executive will report directly to the Chief Executive Officer
of the Company and will perform the duties and responsibilities assigned to her from time to time by the Chief Executive Officer. The Executive will comply with all lawful instructions given by the Chief Executive Officer of the Company.

  

	 	(b)	The terms and conditions of this Agreement will have effect as and from March 1, 2013 and the Executive’s employment as Vice President, Human Resources
will continue until terminated as provided for in this Agreement. 

	 	(c)	The Executive acknowledges and agrees that in addition to the terms and conditions of this Agreement, her employment with the Company is subject to and governed by the
Company’s policies as established from time to time. The Executive agrees to comply with the terms of such policies so long as they are not inconsistent with any provisions of the Agreement. The Executive will inform herself of the details of
such policies and amendments thereto established from time to time. 

  

	 	(d)	The Executive agrees that, as a high technology professional as defined in the Regulations to the Employment Standards Act of British Columbia, and an executive,
her hours of work will vary and may be irregular and will be those hours required to meet the objectives of her employment. The Executive agrees that the compensation described in Section 2 of this Agreement compensates her in full for all
hours worked. 

  

	 	(e)	The Executive will devote herself exclusively to the Company’s business and will not be employed or engaged in any capacity in any other business without the prior
permission of the Company, such permission not to be unreasonably withheld. 

  

	 	(f)	Concurrently with the execution and delivery of this Agreement and in consideration of her employment by the Company, the Executive and the Company will enter into a
“Confidentiality Agreement and Assignment of Inventions” in the form attached hereto as Appendix A. 

  

	2.	REMUNERATION AND BENEFITS 

  

	 	(a)	The Company will pay the Executive an annual salary of $160,000.00 (Canadian funds), less required deductions (the “Base Salary”). The Base Salary will
be payable semi-monthly. 

  

	 	(b)	The Base Salary will be reviewed on an annual basis. This review will not result in a decrease in the Base Salary nor will it necessarily result in an increase to the
Base Salary. 

  

	 	(c)	The Executive will be eligible for an annual cash bonus of up to 20 percent of the Base Salary, if the Chief Executive Officer and the Board of Directors in their
discretion determine that the Executive has achieved the performance objectives agreed to between the Executive and the Chief Executive Officer. Any bonus payable during the first year of the Executive’s employment will be pro-rated.

  

	 	(d)	 The Company will facilitate the Executive’s enrolment in the Company’s insurance benefits plans, as amended from time to time. In all cases,
eligibility to participate in the plans and to receive benefits under the plans will be subject to the terms and requirements of the plans themselves and/or the insurance provider. The Company is not responsible for the payment of benefits in any
circumstance. Further, the Company reserves the right to change any of the insurance benefit 

  
 - 2 -

	 	
plans or providers, however, if the Company is unable to maintain similar coverage as to the insurance benefits plans or the providers, then the Executive will be provided with compensation to
assist in securing her own coverage, such compensation to be determined by the Company. 

  

	 	(e)	The Executive will be eligible for participation in the Company’s share incentive plan, subject to the terms of the plan. 

 

	 	(f)	The Company will reimburse the Executive for all reasonable expenses actually and properly incurred by the Executive in connection with the performance of her duties.
The Executive will provide the Company with receipts supporting her claims for reimbursement. 

  

	3.	VACATION 

 The Executive will be
entitled to an annual paid vacation of four (4) weeks, to be scheduled at times that are mutually acceptable to the Executive and the Company.  
  

	4.	NON-COMPETITION AND NON-SOLICITATION 

  

	 	(a)	The biotechnology industry is highly competitive and employees leaving the employ of the Company have the ability to cause significant damage to the Company’s
interests if they join a competing business immediately upon leaving the Company. 

  

	 	(b)	Definitions: 

  

	 	(i)	“Business” or “Business of the Company” means: 

 

	 	(A)	the researching, developing, production and marketing of RNA interference drugs and delivery technology, as such business grows and evolves during this Agreement; and

  

	 	(B)	any other material business carried on from time to time by the Company or any subsidiary or affiliate of the Company. 

 

	 	(ii)	“Competing Business” means any endeavour, activity or business which is competitive in any material way with the Business of the Company worldwide.

  

	 	(iii)	“Customer” means any entity that is a customer of the Company that the Executive has been directly or indirectly, through her reports, involved in
servicing on behalf of the Company. 

  

	 	(iv)	“Prospective Customer” means any entity during the course of her employment that was solicited by the Executive on behalf of the Company for the
purposes of becoming a customer of the Company or whom she knows was solicited by the Company for the purpose of becoming a customer of the Company. 

  
 - 3 -

	 	(c)	The Executive shall not, during the term of this Agreement and for the Restricted Period (as defined below) following the termination of her employment for any reason,
on her own behalf or on behalf of any entity, whether directly or indirectly, in any capacity whatsoever, alone, through or in connection with any entity, carry on or be employed by or engaged in or have any financial or other interest in or be
otherwise commercially involved in a Competing Business. In this Agreement, “Restricted Period” means: (i) in the event that the Executive is terminated pursuant to Section 6(b) of this Employment Agreement, a period
equivalent to the amount of notice that the Executive is entitled pursuant to Section 6(b)(ii); or (ii) in the event that the Executive’s employment is terminated pursuant to a Change of Control (as defined below), a period of twelve
(12) months. 

  

	 	(d)	The Executive shall, however, not be in default of Section 4(c) by virtue of the Executive: 

 

	 	(i)	following the termination of employment, holding, strictly for portfolio purposes and as a passive investor, no more than five percent (5%) of the issued and
outstanding shares of, or any other interest in, any corporation or other entity that is a Competing Business; or 

  

	 	(ii)	during the course of employment, holding, strictly for portfolio purposes and as a passive investor, no more than five percent (5%) of the issued and outstanding
shares of, or any other interest in, any corporation or other entity, the business of which corporation or other entity is in the same Business as the Company, and provided further that the Executive first obtains the Company’s written consent,
which consent will not be unreasonably withheld. 

  

	 	(e)	If the Executive holds issued and outstanding shares or any other interest in a corporation or other entity pursuant to Section 4(d)(ii) and following the
acquisition of such shares or other interest the business of the corporation or other entity becomes a Competing Business, the Executive will promptly dispose of her shares or other interest in such corporation or other entity.

  

	 	(f)	The Executive shall not, during this Agreement and for the Restricted Period following the termination of her employment, for whatever reason, on her own behalf or on
behalf of or in connection with any other entity, without the prior written and informed consent of the Company, directly or indirectly, in any capacity whatsoever, alone, through or in connection with any entity: 

 

	 	(i)	canvass or solicit the business of (or procure or assist the canvassing or soliciting of the business of) any Customer or Prospective Customer of the Company, or
otherwise solicit, induce or encourage any Customer or Prospective Customer of the Company to cease to engage the services of the Company, for any purpose which is competitive with the Business; or 

  
 - 4 -

	 	(ii)	accept (or procure or assist the acceptance of) any business from any Customer or Prospective Customer of the Company which business is competitive with the Business;
or 

  

	 	(iii)	supply (or procure or assist the supply of) any goods or services to any Customer or Prospective Customer of the Company for any purpose which is competitive with the
Business; or 

  

	 	(iv)	employ, engage, offer employment or engagement to or solicit the employment or engagement of or otherwise entice away from or solicit, induce or encourage to leave the
employment or engagement of the Company, any individual who is employed or engaged by the Company whether or not such individual would commit any breach of her contract or terms of employment or engagement by leaving the employ or the engagement of
the Company; or 

  

	 	(v)	procure or assist any entity to employ, engage, offer employment or engagement or solicit the employment or engagement of any individual who is employed or engaged by
the Company or otherwise entice away from the employment or engagement of the Company any such individual. Notwithstanding the foregoing, the Executive shall, be permitted to, solely in a personal capacity, provide letters of reference for
individuals who are employed by the Company. 

  

	 	(g)	The Executive expressly recognizes and acknowledges that it is the intent of the parties that her activities following the termination of her employment with the
Company be restricted in the manner described in this Agreement, and acknowledges that good, valuable, and sufficient consideration has been provided in exchange for such restrictions. 

 

	5.	INJUNCTIVE RELIEF 

  

	 	(a)	The Executive understands and agrees that the Company has a material interest in preserving the relationships it has developed with its executives, customers and
suppliers against impairment by competitive activities of a former executive. Accordingly, the Executive agrees that the restrictions and covenants contained in Section 4 are reasonably required for the protection of the Company and its
goodwill and that the Executive’s agreement to those restrictions and covenants by the execution of this Agreement, are of the essence to this Agreement and constitute a material inducement to the Company to enter into this Agreement and to
employ the Executive, and that the Company would not enter into this Agreement absent such an inducement. 

  
 - 5 -

	 	(b)	The Executive understands and acknowledges that if the Executive breaches Section 4, that breach will give rise to irreparable injury to the Company for which
damages are an inadequate remedy, and the Company may pursue injunctive relief for such breach in a court of competent jurisdiction. 

  

	6.	TERMINATION 

  

	 	(a)	The Executive may terminate her employment by giving at least three (3) months’ advance notice in writing to the Company of the effective date of the
resignation. The Company may waive such notice, in whole or in part, and if it does so, the Executive’s resignation will become effective and her employment will cease on the date set by the Company in the notice of waiver.

  

	 	(b)	The Company may terminate the Executive’s employment: 

  

	 	(i)	without notice or payment in lieu thereof, for just cause, which for the purposes of this Agreement will be defined to include but not be limited to the
Executive’s willful and continued failure to perform her duties hereunder and the Executive’s willful engagement in conduct that is injurious to the Company, monetarily or otherwise; or 

 

	 	(ii)	at the Company’s sole discretion for any reason, without cause, upon providing to the Executive an amount equal to six (6) months’ Base Salary, (the
“Severance Amount”), plus one additional month of Base Salary for each complete year of service with the Company, to a total maximum Severance Amount of twelve (12) months’ Base Salary. The Company may pay the Severance
Amount by way of a lump sum payment or by way of salary continuance. The Severance Amount is inclusive of any entitlement to minimum standard severance under the B.C. Employment Standards Act. 

 

	 	(c)	In this Agreement, “Change of Control” means the first occurrence of any one of: 

 

	 	(i)	the acquisition or continuing ownership by any person or persons acting jointly or in concert (as such phrase is defined in the Securities Act (British
Columbia)), directly or indirectly, of common shares or of convertible securities, which, when added to all other securities of the Company at the time held by such person or persons, or persons associated or affiliated with such person or persons
within the meaning of the Business Corporations Act (British Columbia) (collectively, the “Acquirors”), and assuming the conversion, exchange or exercise of convertible securities beneficially owned by the Acquirors, results
in the Acquirors beneficially owning shares that would, notwithstanding any agreement to the contrary, entitle the holders thereof for the first time to cast more than 50% of the votes attaching to all shares in the capital of the Company that may
be cast to elect directors; 

  
 - 6 -

	 	(ii)	the sale, lease or exchange or other disposition of all or substantially all of the Company’s assets; 

 

	 	(iii)	an amalgamation, merger, arrangement or other business combination (a “Business Combination”) involving the Company that results in the security
holders of the parties to the Business Combination, other than the Company, owning, directly or indirectly, shares of the continuing entity that entitle the holders thereof to cast more than 50% of the votes attaching to all shares in the capital of
the continuing entity that may be cast to elect directors; or 

  

	 	(iv)	the Company’s Board of Directors, by resolution, determines that a Change of Control of the Company has occurred.” 

 

	 	(d)	If a Change of Control occurs and within twelve (12) months after the occurrence of a Change of Control, the Executive resigns her employment for Good Reason upon
giving the Company not less than three (3) months’ prior written notice of resignation; or at the Company’s sole discretion, the Executive is terminated without cause within twelve (12) months after a Change of Control, the
Executive will be entitled to receive the Change of Control Severance Amount (as defined below). In this Agreement, “Good Reason” means one or more of the following events occurring without the Executive’s written consent:

  

	 	(i)	a fundamental change in the Executive’s status, position, remuneration, authority or responsibilities that does not represent a promotion from or represents an
adverse change from the status, position, authority or responsibilities in effect immediately prior to the Change of Control; 

  

	 	(ii)	a fundamental reduction in the Base Salary or retirement plans, health benefits, bonus potential or other compensation plans, practices, policies or programs provided
to the Executive immediately prior to the Change of Control; 

  

	 	(iii)	relocation of the Executive’s principal place of employment to a place outside of Metro Vancouver; 

 

	 	(iv)	any request by the Company that the Executive participate in an unlawful act pursuant to the laws of British Columbia or Canada; or 

 

	 	(v)	any failure to secure the agreement of any successor company or other entity to the Company to fully assume the Company’s obligations under this Agreement.

  

	 	(e)	In this Agreement, the “Change of Control Severance Amount” means an amount calculated as follows: 

 

	 	(i)	an amount equal to twelve (12) month’s Base Salary; plus 

  
 - 7 -

	 	(ii)	a bonus payment equal to the average of the actual bonus payments made to the Executive from the previous three (3) calendar years preceding the date of
termination of employment. 

  

	 	(f)	No matter how the Executive’s employment is terminated, the Executive will be entitled to any wages and bonus payable for service up to and including the day of
termination. 

  

	7.	RETURN OF MATERIALS UPON TERMINATION OF EMPLOYMENT 

 The Executive will return to the Company all Company documents, files, manuals, books, software, equipment, keys, equipment, identification or credit cards, and all other property belonging to Company
upon the termination of her employment with the Company for any reason. 
  

	8.	GENERAL PROVISIONS 

  

	 	(a)	Non-Waiver. Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other party in default of this
Agreement, irrespective of how long such failure continues, will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default. 

 

	 	(b)	Severability. In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the remaining provisions,
or parts thereof, will be and remain in full force and effect. 

  

	 	(c)	Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the employment of the Executive and supersedes any and all
agreements, understandings, warranties or representations of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and each of the parties releases and forever discharges the other of
and from all manner of actions, causes of action, claim or demands whatsoever under or in respect of any agreement. 

  

	 	(d)	Survival. The provisions of Sections 1(g), 4 and 8(f) will survive the termination of this Agreement. 

 

	 	(e)	Modification of Agreement. Any modification of this Agreement must be in writing and signed by both the Company and the Executive or it will have no effect and
will be void. 

  

	 	(f)	Disputes. Except for disputes arising in respect of Section 4, all disputes arising out of or in connection with this Agreement and the employment
relationship between the parties, are to be referred to and finally resolved by arbitration administered by the British Columbia International Commercial Arbitration Centre, pursuant to its Rules. The place of arbitration will be Vancouver, British
Columbia. 

  
 - 8 -

	 	(g)	Governing Law. This Agreement will be governed by and construed according to the laws of the Province of British Columbia. 

 

	 	(h)	Reimbursement of Legal Fees. The Company will reimburse the Executive for all reasonable and receipted legal fees incurred by the Executive in the negotiation,
drafting, and completion of this Agreement. 

  

	 	(i)	Independent Legal Advice. The Executive agrees that the contents, terms and effect of this Agreement have been explained to her by a lawyer and are fully
understood. The Executive further agrees that the consideration described aforesaid is accepted voluntarily for the purpose of employment with the Company under the terms and conditions described above. 

IN WITNESS WHEREOF this Agreement has been executed by the parties hereto as of the date and year first above written. 

 

							
	  
 SIGNED, SEALED AND DELIVERED

by Diane Gardiner in the presence of:
  

 
	 	 )
 )

)
 )

)
	 		 	 /s/ Diane Gardiner

	 Witness
	 	 )
 )
	 		 	DIANE GARDINER
	 Address
	 	 )
 )
	 		 	
	  
  
	 	 )
 )
	 		 	
		 	)	 		 	
	Occupation	 		 		 	

 TEKMIRA PHARMACEUTICALS CORPORATION 

 

			
	Per:	 	 /s/ Mark J. Murray

		 	Mark J. Murray

  
 - 9 -

 APPENDIX “A” 

CONFIDENTIALITY AGREEMENT 
 AND ASSIGNMENT OF INVENTIONS AGREEMENT 
 THIS AGREEMENT (this
“Agreement”) dated for reference the 1st day of March, 2013 
 BETWEEN: 

TEKMIRA PHARMACEUTICALS CORPORATION  
 (the “Company”), a company incorporated under the laws of 

British Columbia with offices at 100 – 8900 Glenlyon Parkway, 

Burnaby, British Columbia fax: (604) 419-3201 
 AND: 
 DIANE GARDINER (the “Executive”), of 

Surrey, British Columbia 

WHEREAS: 
 A. The Company is in the business of
acquiring, inventing, developing, discovering, adapting and commercializing inventions, methods, processes and products in the fields of chemistry, biochemistry, biotechnology and pharmaceuticals; and 

B. In connection with the employment of the Executive by the Company, the parties desire to establish the terms and conditions under which the Executive
will (i) receive from and disclose to the Company proprietary and confidential information; (ii) agree to keep the information confidential, to protect it from disclosure and to use it only in accordance with the terms of this Agreement;
and (iii) assign to the Company all rights, including any ownership interest which may arise in all inventions and intellectual property developed or disclosed by the Executive over the course of her work during her employment with the Company,
as set out in this Agreement. 
 NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the employment of the Executive by the Company
and the payment by the Company to the Executive of the sum of $10.00 and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 

 

	1.	INTERPRETATION 

  

	1.1	Definitions. In this Agreement: 

  

	 	(a)	“Business” or “Business of the Company” means: 

	 	(i)	the researching, developing, production and marketing of RNA interference drugs and delivery technology, as such business grows and evolves during this Agreement; and

  

	 	(ii)	any other material business carried on from time to time by the Company or any subsidiary or affiliate of the Company. 

 

	 	(b)	“Confidential Information” shall mean any information relating to the Business of the Company, whether or not conceived, originated, discovered or
developed in whole or in part by the Executive, that is not generally known to the public or to other persons who are not bound by obligations of confidentiality and: 

 

	 	(i)	from which the Company derives economic value, actual or potential, from the information not being generally known; or 

 

	 	(ii)	in respect of which the Company otherwise has a legitimate interest in maintaining secrecy; 

and which, without limiting the generality of the foregoing, shall include: 

 

	 	(iii)	all proprietary information licensed to, acquired, used or developed by the Company in its research and development activities (including but not restricted to the
research and development of RNA interference drugs and delivery technology), other scientific strategies and concepts, designs, know-how, information, material, formulas, processes, research data and proprietary rights in the nature of copyrights,
patents, trademarks, licenses and industrial designs; 

  

	 	(iv)	all information relating to the Business of the Company, and to all other aspects of the Company’s structure, personnel and operations, including financial,
clinical, regulatory, marketing, advertising and commercial information and strategies, customer lists, compilations, agreements and contractual records and correspondence; programs, devices, concepts, inventions, designs, methods, processes, data,
know-how, unique combinations of separate items that is not generally known and items provided or disclosed to the Company by third parties subject to restrictions on use or disclosure; 

 

	 	(v)	all know-how relating to the Business of the Company including, all biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical,
clinical, safety, manufacturing and quality control data and information, and all applications, registrations, licenses, authorizations, approvals and correspondence submitted to regulatory authorities; 

  
 2 

	 	(vi)	all information relating to the businesses of competitors of the Company including information relating to competitors’ research and development, intellectual
property, operations, financial, clinical, regulatory, marketing, advertising and commercial strategies, that is not generally known; 

  

	 	(vii)	all information provided by the Company’s agents, consultants, lawyers, contractors, licensors or licensees to the Company and relating to the Business of the
Company; and 

  

	 	(viii)	all information relating to the Executive’s compensation and benefits, including her salary, vacation, stock options, rights to continuing education, perquisites,
severance notice, rights on termination and all other compensation and benefits, except that he shall be entitled to disclose such information to her bankers, advisors, agents, consultants and other third parties who have a duty of confidence to him
and who have a need to know such information in order to provide advice, products or services to him. 

 All Work
Product shall be deemed to be the Company’s Confidential Information. 
  

	 	(c)	“Effective Date” means March 1, 2013, being the date that the Executive started working at the Company, as indicated in her employment
agreement with the Company. 

  

	 	(d)	“Inventions” shall mean any and all inventions, discoveries, developments, enhancements, improvements, concepts, formulas, designs, processes, ideas,
writings and other works, whether or not reduced to practice, and whether or not protectable under patent, copyright, trade secret or similar laws. 

  

	 	(e)	“Work Product” shall mean any and all Inventions and possible Inventions relating to the Business of the Company and which the Executive may make or
conceive, alone or jointly with others, during her involvement in any capacity with the Company, whether during or outside her regular working hours, except those Inventions made or conceived by the Executive entirely on her own time that do not
relate to the Business of the Company and do not derive from any equipment, supplies, facilities, Confidential Information or other information, gained, directly or indirectly, from or through her involvement in any capacity with the Company.

  

	2.	CONFIDENTIALITY 

 2.1 Basic Obligation
of Confidentiality. The Executive hereby acknowledges and agrees that in the course of her involvement with the Company, the Company may disclose to him or he may otherwise have access or be exposed to Confidential Information. The Company
hereby agrees to provide such access to the Executive and the Executive hereby agrees to receive and hold all Confidential Information on the terms and conditions set out in this Agreement. 

  
 3 

 
Except as otherwise set out in this Agreement, the Executive will keep strictly confidential all Confidential Information and all other information belonging to the Company that he acquires,
observes or is informed of, directly or indirectly, in connection with her involvement, in any capacity, with the Company. 
 2.2 Fiduciary
Capacity. The Executive will be and act toward the Company as a fiduciary in respect of the Confidential Information. 
 2.3
Non-disclosure. Except with the prior written consent of the Company, the Executive will not at any time, either during or after her involvement in any capacity with the Company; 

 

	 	(a)	use or copy any Confidential Information or recollections thereof for any purpose other than the performance of her duties for the benefit of the Company;

  

	 	(b)	publish or disclose any Confidential Information or recollections thereof to any person other than to employees of the Company who have a need to know such Confidential
Information in the performance of their duties for the Company; 

  

	 	(c)	permit or cause any Confidential Information to be used, copied, published, disclosed, translated or adapted except as otherwise expressly permitted by this Agreement;
or 

  

	 	(d)	permit or cause any Confidential Information to be stored off the premises of the Company, including permitting or causing such Confidential Information to be stored in
electronic format on personal computers, except in accordance with written procedures of the Company, as amended from time to time in writing. 

 2.4 Taking Precautions. The Executive will take all reasonable precautions necessary or prudent to prevent material in her possession or control that contains or refers to Confidential Information
from being discovered, used or copied by third parties. 
 2.5 The Company’s Ownership of Confidential Information. As between the
Executive and the Company, the Company shall own all right, title and interest in and to the Confidential Information, whether or not created or developed by the Executive. 
 2.6 Control of Confidential Information and Return of Information. All physical materials produced or prepared by the Executive containing Confidential Information, including, without limitation,
records, devices, computer files, data, notes, reports, proposals, lists, correspondence, specifications, drawings, plans, materials, accounts, reports, financial statements, estimates and all other materials prepared in the course of her
responsibilities to or for the benefit of the Company, together with all copies thereof (in whatever medium recorded), shall belong to the Company, and the Executive will promptly turn over to the Company’s possession every original and copy of
any and all such items in her possession or control upon request by the Company. If the material is such that it cannot reasonably be delivered, upon request from the Company, the Executive will provide reasonable evidence that such materials have
been destroyed, purged or erased. 

  
 4 

 2.7 Purpose of Use. The Executive agrees that he will use Confidential Information only for purposes
authorized or directed by the Company. 
 2.8 Exemptions. The obligations of confidentiality set out in this Article 2 will not apply to
any of the following: 
  

	 	(a)	information that is already known to the Executive, though not due to a prior disclosure by the Company or by a person who obtained knowledge of the information,
directly or indirectly, from the Company; 

  

	 	(b)	information disclosed to the Executive by another person who is not obliged to maintain the confidentiality of that information and who did not obtain knowledge of the
information, directly or indirectly, from the Company; 

  

	 	(c)	information that is developed by the Executive independently of Confidential Information received from the Company and such independent development can be documented by
the Executive; 

  

	 	(d)	other particular information or material which the Company expressly exempts by written instrument signed by the Company; 

 

	 	(e)	information or material that is in the public domain through no fault of the Executive; and 

 

	 	(f)	information required by operation of law, court order or government agency to be disclosed, provided that: 

 

	 	(i)	in the event that the Executive is required to disclose such information or material, upon becoming aware of the obligation to disclose, the Executive will provide to
the Company prompt written notice so that the Company may seek a protective order or other appropriate remedy and/or waive compliance with the provisions of this Agreement; 

 

	 	(ii)	if the Company agrees that the disclosure is required by law, it will give the Executive written authorization to disclose the information for the required purposes
only; 

  

	 	(iii)	if the Company does not agree that the disclosure is required by law, this Agreement will continue to apply, except to the extent that a Court of competent jurisdiction
orders otherwise; and 

  

	 	(iv)	 if a protective order or other remedy is not obtained or if compliance with this Agreement is waived, the Executive will furnish only that portion of

  
 5 

	 	
the Confidential Information that is legally required and will exercise all reasonable efforts to obtain confidential treatment of such Confidential Information. 

 

	3.	ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS 

3.1 Notice of Invention. The Executive agrees to promptly and fully inform the Company of all Work Product, whether or not patentable, throughout
the course of her involvement, in any capacity, with the Company, whether or not developed before or after execution of this Agreement. On her ceasing to be employed by the Company for any reason whatsoever, the Executive will immediately deliver up
to the Company all Work Product. 
 3.2 Assignment of Rights. Subject only to the exceptions set out in Exhibit I attached to this
Agreement, the Executive will assign, and does hereby assign, to the Company or, at the option of the Company and upon notice from the Company, to the Company’s designee, all of her right, title and interest in and to all Work Product and all
other rights and interests of a proprietary nature in and associated with the Work Product, including all patents, patent applications filed and other registrations granted thereon. To the extent that the Executive retains or acquires legal title to
any such rights and interests, the Executive hereby declares and confirms that such legal title is and will be held by him only as trustee and agent for the Company. The Executive agrees that the Company’s rights hereunder shall attach to all
Work Product, notwithstanding that it may be perfected or reduced to specific form after he has terminated her relationship with the Company. The Executive further agrees that the Company’s rights hereunder are worldwide rights and are not
limited to Canada, but shall extend to every country of the world. 
 3.3 Moral Rights. Without limiting the foregoing, the Executive
hereby irrevocably waives any and all moral rights arising under the Copyright Act (Canada), as amended, or any successor legislation of similar force and effect or similar legislation in other applicable jurisdictions or at common law that
he may have with respect to all Work Product, and agrees never to assert any moral rights which he may have in the Work Product, including, without limitation, the right to the integrity of the Work Product, the right to be associated with the Work
Product, the right to restrain or claim damages for any distortion, mutilation or other modification or enhancement of the Work Product and the right to restrain the use or reproduction of the Work Product in any context and in connection with any
product, service, cause or institution, and the Executive further confirms that the Company may use or alter any Work Product as the Company sees fits in its absolute discretion. 
 3.4 Goodwill. The Executive hereby agrees that all goodwill he has established or may establish with clients, customers, suppliers, principals, shareholders, investors, collaborators, strategic
partners, licensees, contacts or prospects of the Company relating to the Business of the Company (or of its partners, subsidiaries or affiliates), both before and after the Effective Date, shall, as between the Executive and the Company, be and
remain the property of the Company exclusively, for the Company to use, alter, vary, adapt and exploit as the Company shall determine in its discretion. 

  
 6 

 3.5 Assistance. The Executive hereby agrees to reasonably assist the Company, at the Company’s
request and expense, in: 
  

	 	(a)	making patent applications for all Work Product, including instructions to lawyers and/or patent agents as to the characteristics of the Work Product in sufficient
detail to enable the preparation of a suitable patent specification, to execute all formal documentation incidental to an application for letters patent and to execute assignment documents in favour of the Company for such applications;

  

	 	(b)	making applications for all other forms of intellectual property registration relating to all Work Product; 

 

	 	(c)	prosecuting and maintaining the patent applications and other intellectual property relating to all Work Product; and 

 

	 	(d)	registering, maintaining and enforcing the patents and other intellectual property registrations relating to all Work Product. 

If the Company is unable for any reason to secure the Executive’s signature with respect to any Work Product including, without limitation, to apply
for or to pursue any application for any patents or copyright registrations covering such Work Product, then the Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as her agent and
attorney-in-fact, to act for and in her behalf and stead to execute and file any papers, oaths and to do all other lawfully permitted acts with respect to such Work Product with the same legal force and effect as if executed by him. 

3.6 Assistance with Proceedings. The Executive further agrees to reasonably assist the Company, at the Company’s request and expense, in
connection with any defence to an allegation of infringement of another person’s intellectual property rights, claim of invalidity of another person’s intellectual property rights, opposition to, or intervention regarding, an application
for letters patent, copyright or trademark or other proceedings relating to intellectual property or applications for registration thereof. 

3.7 Commercialization. The Executive understands that the decision whether or not to commercialize or market any Work Product is within the
Company’s sole discretion and for the Company’s sole benefit and that no royalty or other consideration will be due or payable to him as a result of the Company’s efforts to commercialize or market any such Work Product. 

3.8 Prior Inventions. In order to have them excluded from this Agreement, the Executive has set forth on Exhibit I attached to this Agreement a
complete list of all Inventions for which a patent application has not yet been filed that he has, alone or jointly with others, conceived, developed or reduced to practice prior to the execution of this Agreement to which he has any right, title or
interest, and which relate to the Business of the Company. If such list is blank or no such list is attached, the Executive represents and warrants that there are no such prior Inventions. 

  
 7 

	4.	GENERAL 

 4.1 Term. Subject to
Section 4.10, the term of this Agreement is from the Effective Date and terminates on the date that the Executive is no longer working at or for the Company in any capacity. 
 4.2 No Conflicting Obligations. The Executive hereby represents and warrants that he has no agreements with or obligations to any other person with respect to the matters covered by this Agreement
or concerning the Confidential Information that are in conflict with anything in this Agreement, except as disclosed in Exhibit I attached to this Agreement. 
 4.3 Publicity. The Executive shall not, without the prior written consent of the Company, make or give any public announcements, press releases or statements to the public or the press regarding
any Work Product or any Confidential Information. 
 4.4 Further Assurances. The parties will execute and deliver to each other such
further instruments and assurances and do such further acts as may be required to give effect to this Agreement. 
 4.5 Notices. All
notices and other communications that are required or permitted by this Agreement must be in writing and shall be hand delivered or sent by express delivery service or certified or registered mail, postage prepaid, or by facsimile transmission (with
receipt confirmed in writing) to the parties at the addresses on page 1 of this Agreement. Any such notice shall be deemed to have been received on the earlier of the date actually received or the date five (5) days after the same was posted or
sent. Either party may change its address or its facsimile number by giving the other party written notice, delivered in accordance with this section. 
 4.6 Equitable Remedies. The Executive understands and acknowledges that if he breaches any of her obligations under this Agreement, that breach may give rise to irreparable injury to the Company
for which damages are an inadequate remedy. In the event of any such breach by the Executive, in addition to all other remedies available to the Company at law or in equity, the Company will be entitled as a matter of right to apply to a court of
competent jurisdiction for such relief by way of restraining order, injunction, decree or otherwise, as may be appropriate to ensure compliance with the provisions of this Agreement. 
 4.7 Non-Waiver. Failure on the part of either party to complain of any act or failure to act of the other of them or to declare the other party in default of this Agreement, irrespective of how
long such failure continues, will not constitute a waiver by such party of their rights hereunder or of the right to then or subsequently declare a default. 
 4.8 Severability. In the event that any provision or part of this Agreement is determined to be void or unenforceable in whole or in part, the remaining provisions, or parts thereof, will be and
remain in full force and effect. 

  
 8 

 4.9 Entire Agreement. This Agreement constitutes the entire agreement between the parties with
respect to the subject matter hereof and supersedes any and all agreements, understandings, warranties or representations of any kind, written or oral, express or implied, including any relating to the nature of the position or its duration, and
each of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claim or demands whatsoever under or in respect of any agreement. 
 4.10 Survival. Notwithstanding the expiration or early termination of this Agreement, the provisions of Article 1, Article 2 (including the obligations of confidentiality and to return Confidential
Information, which shall endure, with respect to each item of Confidential Information, for so long as those items fall within the definition of Confidential Information), Sections 3.2, 3.3, 3.4, 3.5 and 3.6 and Article 4 shall survive any
expiration or early termination of this Agreement. 
 4.11 Modification of Agreement. Any modification of this Agreement must be in
writing and signed by both the Company and the Executive or it will have no effect and will be void. 
 4.12 Governing Law. This
Agreement will be governed by and construed according to the laws of the Province of British Columbia. 
 4.13 Reimbursement of Legal
Fees. The Company will reimburse the Executive for all reasonable and receipted legal fees incurred by the Executive in the negotiation, drafting, and completion of this Agreement. 

  
 9 

 4.14 Independent Legal Advice. The Executive agrees that he has obtained or has had an opportunity to
obtain independent legal advice in connection with this Agreement, and further acknowledge that he has read, understands, and agrees to be bound by all of the terms and conditions contained herein. 

IN WITNESS WHEREOF this Agreement has been executed by the parties hereto as of the date and year first above written. 

 

							
	  
 SIGNED, SEALED AND DELIVERED

by DIANE GARDINER in the presence of:
  

 
	 	 )
 )

)
 )

)
	 		 	 /s/ Diane Gardiner

	 Witness Signature
  
	 	 )
 )
	 		 	DIANE GARDINER
	 Witness Name
  
	 	 )
 )
	 		 	
	 Witness Address
  
	 	 )
 )
	 		 	
	  
  
	 	 )
 )
	 		 	
	Witness Occupation	 	)	 		 	

 TEKMIRA PHARMACEUTICALS CORPORATION 

 

			
	Per:	 	 /s/ Mark J. Murray

		 	Mark J. Murray

  
 10 

 EXHIBIT I 
 to Confidentiality Agreement and Assignment of Inventions 
 EXCLUSIONS
FROM WORK PRODUCT 
 None.EX-4.1

 Exhibit 4.1 
 EXECUTION VERSION 
 UNITED STATES STEEL CORPORATION, 

Issuer 

and 

THE BANK OF NEW YORK MELLON, 
 Trustee 
 SIXTH SUPPLEMENTAL INDENTURE 

DATED AS OF MARCH 26, 2013 
 TO INDENTURE 
 DATED AS OF MAY 21, 2007 

Relating To 
 $275,000,000 6.875% Senior Notes due April 1, 2021 

 SIXTH SUPPLEMENTAL INDENTURE 

SIXTH SUPPLEMENTAL INDENTURE, dated as of March 26, 2013 (the “Supplemental Indenture”), to the Indenture
(defined below) between United States Steel Corporation (the “Company”), a Delaware corporation, and The Bank of New York Mellon, a New York banking corporation, as Trustee (the “Trustee”). 

RECITALS 
 WHEREAS, the Company has heretofore executed and delivered to the Trustee an Indenture, dated as of May 21, 2007 (the “Base Indenture”), providing for the issuance from time
to time of its notes and other evidences of senior debt securities, to be issued in one or more series as therein provided; 

WHEREAS, pursuant to the terms of the Base Indenture, the Company desires to provide for the establishment of a new series of its
Securities to be known as its 6.875% Senior Notes due 2021 (the “Notes”), the form and substance of such Notes and the terms, provisions and conditions thereof to be set forth as provided in the Base Indenture and this Supplemental
Indenture (together, the “Indenture”); and 
 WHEREAS, the Company has requested that the Trustee
execute and deliver this Supplemental Indenture, and all requirements necessary to make this Supplemental Indenture a valid instrument in accordance with its terms, and to make the Notes, when executed by the Company and authenticated and delivered
by the Trustee, the valid and legally binding obligations of the Company, and all acts and things necessary have been done and performed to make this Supplemental Indenture enforceable in accordance with its terms, and the execution and delivery of
this Supplemental Indenture has been duly authorized in all respects. 
 WITNESSETH: 

NOW, THEREFORE, for and in consideration of the premises contained herein, each party agrees for the benefit of each other party
and for the equal and ratable benefit of the Holders of the Notes, as follows: 
 ARTICLE ONE 

DEFINITIONS 

Section 1.01. Capitalized terms used but not defined in this Supplemental Indenture shall have the meanings ascribed to them
in the Base Indenture. 
 Section 1.02. References in this Supplemental Indenture to article and section numbers
shall be deemed to be references to article and section numbers of this Supplemental Indenture unless otherwise specified. 

Section 1.03. For purposes of this Supplemental Indenture, the following terms have the meanings ascribed to them as follows:

 “Attributable Debt” means, with respect to any sale and leaseback transaction, at the time of determination,
the lesser of (1) the sale price of the property so leased multiplied by a fraction the numerator of which is the remaining portion of the base term of the lease included in such transaction and the denominator of which is the base term of such
lease, and (2) the total obligation (discounted to the present value at the implicit interest factor, determined in accordance with GAAP, included in the rental payments) of the lessee for rental payments (other than amounts required to be paid
on account of property taxes as well as maintenance, repairs, insurance, water rates and other items which do not constitute payments for property rights) during the remaining portion of the base term of the lease included in such transaction.

  
 1 

 “Base Indenture” has the meaning provided in the recitals. 

“Change of Control” has the meaning provided in Section 4.02. 

“Change of Control Repurchase Event” has the meaning provided in Section 4.02. 

“Comparable Treasury Issue” has the meaning provided in Section 4.01. 

“Comparable Treasury Price” has the meaning provided in Section 4.01. 

“Consolidated Net Tangible Assets” means, as of the time of determination, the aggregate amount of the assets of the
Company and the assets of its consolidated Subsidiaries after deducting (1) all goodwill, trade names, trademarks, service marks, patents, unamortized debt discount and expense and other intangible assets and (2) all current liabilities,
as reflected on the most recent consolidated balance sheet prepared by the Company in accordance with GAAP contained in an annual report on Form 10-K or a quarterly report on Form 10-Q timely filed or any amendment thereto (and not subsequently
disclaimed as not being reliable by the Company) pursuant to the Exchange Act by the Company prior to the time as of which “Consolidated Net Tangible Assets” is being determined. 

“Depositary” has the meaning provided in Section 2.03. 

“Guarantee” means any obligation, contingent or otherwise, of any Person directly or indirectly guaranteeing any
Indebtedness of any other Person and any obligation, direct or indirect, contingent or otherwise, of such Person (1) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness of such other Person (whether
arising by virtue of partnership arrangements, or by agreement to keep well, to purchase assets, goods, securities or services, to take or pay or to maintain financial statement conditions or otherwise) or (2) entered into for purposes of
assuring in any other manner the obligee of such Indebtedness of the payment thereof or to protect such obligee against loss in respect thereof (in whole or in part); provided, however, that the term “Guarantee” shall not
include endorsements for collection or deposit in the ordinary course of business. The term “Guarantee,” when used as a verb, shall have a correlative meaning. 
 “Incur” means issue, assume, Guarantee or otherwise become liable for Indebtedness. 

  
 2 

 “Indebtedness” means, with respect to any Person, obligations of such
Person for borrowed money (including without limitation, Indebtedness for borrowed money evidenced by notes, bonds, debentures or similar instruments). 
 “Independent Investment Banker” has the meaning provided in Section 4.01. 
 “Indenture” has the meaning provided in the recitals. 

“Interest Payment Date” has the meaning provided in Section 2.04. 

“Investment Grade” has the meaning provided in Section 4.02. 

“Liens” has the meaning provided in Section 3.01. 

“Moody’s” has the meaning provided in Section 4.02. 

“Notes” has the meaning provided in the recitals. 

“Primary Treasury Dealer” has the meaning provided in Section 4.01. 

“Principal Property” means any domestic blast furnace or steel producing facility, or casters that are part of a plant
that includes such a facility, in each case located in the United States, having a net book value in excess of 1% of Consolidated Net Tangible Assets at the time of determination. 

“Rating Agency” has the meaning provided in Section 4.02. 

“Rating Category” has the meaning provided in Section 4.02. 

“Rating Date” has the meaning provided in Section 4.02. 

“Ratings Event” has the meaning provided in Section 4.02. 

“Reference Treasury Dealer” has the meaning provided in Section 4.01. 

“Reference Treasury Dealer Quotations” has the meaning provided in Section 4.01. 

“Refinance” means, in respect of any Indebtedness, to refinance, extend, renew, refund, repay, prepay, redeem, defease
or retire, or to issue other Indebtedness in exchange or replacement for, such Indebtedness. “Refinanced” and “Refinancing” shall have correlative meanings. 

“S&P” has the meaning provided in Section 4.02. 

“Subsidiary” means, with respect to any Person (the “Parent”) at any date, any corporation, limited
liability company, partnership, association or other entity of which a majority of the shares or securities or other interests having ordinary voting power for the election of directors or another governing body (other than securities or interests
having such power only by reason of the happening of a contingency) are at the time beneficially owned directly or indirectly through one or more intermediaries, or both, by the Parent. 

  
 3 

 “Supplemental Indenture” has the meaning provided in the preamble.

 “Treasury Yield” has the meaning provided in Section 4.01. 

“Trustee” has the meaning provided in the preamble. 

“Voting Stock” has the meaning provided in Section 4.02. 

ARTICLE TWO 
 GENERAL TERMS AND CONDITIONS OF THE NOTES 
 Section 2.01.
Designation and Principal Amount. 
 The Notes are hereby authorized and are designated the 6.875% Senior Notes due 2021,
unlimited in aggregate principal amount. The Notes issued on the date hereof pursuant to the terms of this Indenture shall be in an aggregate principal amount of $275,000,000, which amount shall be set forth in the written order of the Company for
the authentication and delivery of the Notes pursuant to Section 3.03 of the Base Indenture. In addition, the Company may issue, from time to time in accordance with the provisions of this Indenture, additional Notes having the same terms and
conditions as the Notes issued on the date hereof in all respects (except for the payment of interest accruing prior to the issue date of such additional Notes), so that such additional Notes shall be consolidated and form a single series with the
Notes issued on the date hereof and shall be governed by the terms of this Indenture; provided that if any such additional Notes are not fungible with the Notes issued on the date hereof for U.S. federal income tax purposes, such additional
Notes shall have a separate CUSIP number. 
 Section 2.02. Maturity. 

The principal amount of the Notes shall be payable on April 1, 2021. 

Section 2.03. Form and Payment. 
 The Notes shall be issued as global notes, in fully registered book-entry form without coupons in denominations of $1,000 and integral multiples thereof. 

Principal, premium, if any, and/or interest, if any, on the global notes representing the Notes shall be made to The Depository Trust
Company (the “Depositary”). 
 The global notes representing the Notes shall be deposited with, or on behalf
of, the Depositary and shall be registered in the name of the Depositary or a nominee of the Depositary. No global note may be transferred except as a whole by a nominee of the Depositary to the Depositary or to another nominee of the Depositary, or
by the Depositary or such nominee to a successor of the Depositary or a nominee of such successor. 

  
 4 

 The Bank of New York Mellon shall act as Paying Agent for the Notes. The Company may choose
to pay interest by mailing checks or making wire or other electronic funds transfers. All money paid by the Company to any Paying Agent that remains unclaimed at the end of two years after the amount is due to Holders shall be repaid to the Company.
After such two-year period, Holders may look only to the Company for payment and not to the Trustee, any other Paying Agent or anyone else. The Company may also arrange for additional payment offices, and may cancel or change these offices,
including any use of the Trustee’s corporate trust office. The Company may appoint or change any Paying Agent without prior notice to any Holder. 
 Section 2.04. Interest. 
 Interest on the Notes shall accrue at
the rate of 6.875% per annum. Interest on the Notes shall accrue from March 26, 2013 or the most recent interest payment date on which interest was paid. Interest on the Notes shall be payable semiannually in arrears on April 1 and
October 1, commencing on October 1, 2013 (each an “Interest Payment Date”), to the Holders in whose names the Notes are registered at the close of business on the March 15 and September 15 immediately preceding
such Interest Payment Date. Interest on the Notes shall be computed on the basis of a 360-day year comprised of twelve 30-day months. 
 ARTICLE THREE 
 ADDITIONAL COVENANTS 

Section 3.01. Limitation on Liens. 
 The Company shall not Incur, and shall not permit any of its Subsidiaries to Incur, any Indebtedness for borrowed money secured by a mortgage, security interest, pledge, lien, charge or other similar
encumbrance (collectively, “Liens”) upon (a) any Principal Property of the Company or any Principal Property of a Subsidiary or (b) any shares of stock or other equity interests or Indebtedness of any Subsidiary that owns
a Principal Property (whether such Principal Property, shares of stock or other equity interests or Indebtedness is now existing or owned or hereafter created or acquired), in each case, unless prior to or at the same time, the Notes (together with,
at the option of the Company, any other Indebtedness of the Company or any Subsidiary ranking equally in right of payment with the Notes) are equally and ratably secured with or, at the option of the Company, prior to, such Indebtedness. 

Any Lien created for the benefit of Holders pursuant to the preceding sentence shall provide by its terms that such Lien shall be
automatically and unconditionally released and discharged upon the release and discharge of such Lien. 
 The foregoing
restriction does not apply, with respect to any Person, to any of the following: 
  

	 	(i)	leases to which such Person is a party, or deposits to secure public or statutory obligations of such Person or deposits of cash or United States government bonds to
secure surety or appeal bonds to which such Person is a party, or deposits as security for contested taxes or import duties or for the payment of rent, in each case Incurred in the ordinary course of business; 

  
 5 

	 	(ii)	Liens imposed by law, such as carriers’, warehousemen’s and mechanics’ Liens, in each case for sums not yet overdue by more than 30 days or being
contested in good faith by appropriate proceedings or other Liens arising out of judgments or awards against such Person with respect to which such Person shall then be proceeding with an appeal or other proceedings for review and Liens arising
solely by virtue of any statutory or common law provision relating to banker’s Liens, rights of set-off or similar rights and remedies as to deposit accounts or other funds maintained with a creditor depository institution; provided,
however, that (A) such deposit account is not a dedicated cash collateral account and is not subject to restrictions against access by the Company in excess of those set forth by regulations promulgated by the Federal Reserve Board and
(B) such deposit account is not intended by the Company to provide collateral to the Depositary; 

  

	 	(iii)	Liens for property taxes not yet subject to penalties for non-payment or which are being contested in good faith by appropriate proceedings; 

 

	 	(iv)	minor survey exceptions, minor encumbrances, easements or reservations of, or rights of others for, licenses, rights-of-way, sewers, electric lines, telegraph and
telephone lines and other similar purposes, or zoning or other restrictions as to the use of real property or Liens incidental to the conduct of the business of such Person or to the ownership of its properties which were not Incurred in connection
with Indebtedness and which do not in the aggregate materially adversely affect the value of said properties or materially impair their use in the operation of the business of such Person; 

 

	 	(v)	Liens securing Indebtedness Incurred to finance the construction, purchase or lease of, or repairs, improvements or additions to, property, plant or equipment of such
Person; provided, however, that the Lien may not extend to any other property owned by such Person at the time the Lien is Incurred (other than assets and property affixed or appurtenant thereto), and the Indebtedness (other than any
interest thereon) secured by the Lien may not be Incurred more than 180 days after the later of the acquisition, completion of construction, repair, improvement, addition or commencement of full operation of the property subject to the Lien;

  

	 	(vi)	Liens existing on the issue date of the Notes; 

  

	 	(vii)	Liens on property or shares of capital stock of another Person at the time such other Person becomes a Subsidiary of such Person; provided, however, that the
Liens may not extend to any other property owned by such Person (other than assets and property affixed or appurtenant thereto); 

  

	 	(viii)	Liens securing industrial revenue or pollution control bonds issued for the benefit of the Company; 

  
 6 

	 	(ix)	Liens on property at the time such Person or any of its Subsidiaries acquires the property, including any acquisition by means of a merger or consolidation with or into
such Person or a Subsidiary of such Person; provided, however, that the Liens may not extend to any other property owned by such Person (other than assets and property affixed or appurtenant thereto); 

 

	 	(x)	Liens securing Indebtedness or other obligations of a Subsidiary of such Person owing to such Person or a wholly-owned Subsidiary of such Person;

  

	 	(xi)	Liens to secure any Refinancing (or successive Refinancings) as a whole, or in part, of any Indebtedness secured by any Lien referred to in the foregoing clauses (v),
(vi), (vii), (viii) or (ix); provided, however, that: (a) such new Lien shall be limited to all or part of the same property and assets that secured or, under the written agreements pursuant to which the original Lien arose,
could secure the original Lien (plus improvements and accessions to, such property or proceeds or distributions thereof); and (b) the Indebtedness secured by such Lien at such time is not increased to any amount greater than the sum of
(x) the outstanding principal amount or, if greater, committed amount of the Indebtedness under clauses (v), (vi), (vii), (viii) or (ix) at the time the original Lien became a Lien permitted under the Indenture and (y) an amount
necessary to pay any fees and expenses, including premiums, related to such Refinancing, refunding, extension, renewal or replacement; and 

  

	 	(xii)	Liens on assets subject to a sale and leaseback transaction securing Attributable Debt permitted to be Incurred pursuant to Section 3.02. 

Notwithstanding the foregoing restrictions, the Company and its Subsidiaries shall be permitted to Incur Indebtedness secured by a Lien
which would otherwise be subject to the foregoing restrictions without equally and ratably securing the Notes, if any, provided that, after giving effect to such Indebtedness, the aggregate amount of all Indebtedness secured by Liens (not
including Liens permitted under clauses (i) through (xii) above), together with all Attributable Debt outstanding pursuant to the second paragraph of Section 3.02, does not exceed 15% of the Consolidated Net Tangible Assets of the
Company calculated as of the date of the creation or incurrence of the Lien. The Company and its Subsidiaries also may, without equally and ratably securing the Notes, create or Incur Liens that extend, renew, substitute or replace (including
successive extensions, renewals, substitutions or replacements), in whole or in part, any Lien permitted pursuant to the preceding sentence. 
 Section 3.02. Limitation on Sale and Leaseback Transactions. 

The Company shall not directly or indirectly, and shall not permit any of its Subsidiaries that own a Principal Property directly or
indirectly to, enter into any sale and leaseback transaction for the sale and leasing back of any Principal Property, whether now owned or hereafter acquired, unless: 
  

	 	(i)	such transaction was entered into prior to the date of issuance of the Notes (other than any additional Notes); 

  
 7 

	 	(ii)	such transaction was for the sale and leasing back to the Company or one of its Subsidiaries of any property by the Company or one of its Subsidiaries;

  

	 	(iii)	such transaction involves a lease for not more than three years (or which may be terminated by the Company or its Subsidiaries within a period of not more than three
years); 

  

	 	(iv)	the Company would be entitled to Incur Indebtedness secured by a Lien with respect to such sale and leaseback transaction without equally and ratably securing the Notes
pursuant to the last paragraph of Section 3.01; or 

  

	 	(v)	the Company applies an amount equal to the net proceeds from the sale of such property to the purchase of other property or assets used or useful in its business or to
the retirement of long-term Indebtedness within 365 days before or after the effective date of any such sale and leaseback transaction; provided that, in lieu of applying such amount to the retirement of long-term Indebtedness, the Company
may deliver Notes of both series to the Trustee for cancellation, such Notes to be credited at the cost thereof to it. 

 Notwithstanding the restrictions set forth in the preceding paragraph, the Company and its Subsidiaries may enter into any sale and leaseback transaction which would otherwise be subject to the foregoing
restrictions, if after giving effect thereto the aggregate amount of all Attributable Debt with respect to such transactions, together with all Indebtedness outstanding pursuant to the last paragraph of Section 3.01, does not exceed 15% of the
Consolidated Net Tangible Assets of the Company calculated as of the closing date of the sale and leaseback transaction. 

ARTICLE FOUR 
 REDEMPTION OF THE NOTES 
 Section 4.01. Optional Redemption.

 On and after April 1, 2017, the Company may redeem the Notes at the its option, at any time in whole or from time to
time in part, upon not less than 30 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of principal amount) listed below, plus accrued and unpaid interest on the Notes, if any, to, but excluding, the applicable
redemption date, if redeemed during the twelve-month period beginning on April 1 of each of the years indicated below. 
  

					
	 On or after:
	  	Price:	 
	 2017
	  	 	103.438	% 
	 2018
	  	 	101.719	% 
	 2019 and thereafter
	  	 	100.000	% 

  
 8 

 At any time prior to April 1, 2017, the Company may also redeem the Notes, at its
option, at any time in whole, or from time to time, in part, at a price equal to the greater of: 
  

	 	(i)	100% of the principal amount of the Notes to be redeemed; or 

  

	 	(ii)	the sum of the present values of the redemption price of the Notes to be redeemed if they were redeemed on April 1, 2017 (as described in the prior paragraph) and
all required interest payments due on such Notes through April 1, 2017, exclusive of interest accrued to the date of redemption, discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day
months) at the applicable Treasury Yield plus 50 basis points, 

 plus accrued and unpaid interest, if any, to,
but excluding, the date of redemption. 
 The Notes called for redemption become due on the date fixed for redemption. Notices
of redemption shall be mailed by first-class mail at least 30 but not more than 60 days before the redemption date to each Holder of Notes to be redeemed at its registered address. The notice of redemption for the Notes shall state the amount to be
redeemed. On and after the redemption date, interest shall cease to accrue on any Notes that are redeemed. If less than all of the Notes are redeemed at any time, the Trustee shall select Notes on a pro rata basis or by any other method the Trustee
deems fair and appropriate. 
 Any redemption may, in the Company’s discretion, be subject to the satisfaction of one or
more conditions precedent. 
 For purposes of determining the optional redemption price, the following definitions are
applicable: 
 “Comparable Treasury Issue” means the United States Treasury security selected by the
Independent Investment Banker as having a maturity comparable to the period from the redemption date to April 1, 2017 that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of
corporate debt securities of comparable maturity. 
 “Comparable Treasury Price” means, with respect to any
redemption date, the average of the Reference Treasury Dealer Quotations obtained by the Company for that redemption date, after excluding the highest and lowest of such Reference Treasury Dealer Quotations, or, if the Company is unable to obtain at
least four such Reference Treasury Dealer Quotations, the average of all Reference Treasury Dealer Quotations obtained by the Company. 
 “Independent Investment Banker” means J.P. Morgan Securities LLC, or, if such firm is unwilling or unable to select the applicable Comparable Treasury Issue, an independent investment
banking institution of national standing appointed by the Company. 
 “Reference Treasury Dealer” means J.P.
Morgan Securities LLC and its successors, and at least two other primary U.S. government securities dealers in New York City (each, a “Primary Treasury Dealer”) selected by the Independent Investment Banker; provided,
however, that if any of the foregoing shall cease to be a Primary Treasury Dealer, the Company shall substitute therefor another Primary Treasury Dealer. 

  
 9 

 “Reference Treasury Dealer Quotations” means, with respect to each
Reference Treasury Dealer and any redemption date for the Notes, an average, as determined by the Company, of the bid and asked prices for the Comparable Treasury Issue for the Notes, expressed in each case as a percentage of its principal amount,
quoted in writing to the Trustee by the Reference Treasury Dealer at 3:30 p.m., New York City time, on the third business day preceding the redemption date. 
 “Treasury Yield” means, with respect to any redemption date applicable to the Notes, the rate per annum equal to the semiannual equivalent yield to maturity, computed as of the third
business day immediately preceding the redemption date, of the Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue, expressed as a percentage of its principal amount, equal to the applicable Comparable Treasury Price for
the redemption date. 
 Section 4.02. Purchase of Notes Upon a Change of Control Repurchase Event.

 If a Change of Control Repurchase Event occurs, unless the Company has exercised its right to redeem the Notes pursuant to
the Indenture, the Company shall be required to make an offer to each Holder of the Notes to repurchase all or any part (in excess of $1,000 and in integral multiples of $1,000) of that Holder’s Notes at a repurchase price in cash equal to 101%
of the aggregate principal amount of the Notes repurchased plus any accrued and unpaid interest on the Notes repurchased to, but not including, the date of repurchase. Within 30 days following any Change of Control Repurchase Event or, at the option
of the Company, prior to any Change of Control, but after the public announcement of the Change of Control, the Company shall mail a notice to each Holder, with a copy to the Trustee, describing the transaction or transactions that constitute or may
constitute the Change of Control Repurchase Event and offering to repurchase the Notes on the payment date specified in the notice, which date shall be no earlier than 30 days and no later than 60 days from the date such notice is mailed. The notice
shall, if mailed prior to the date of consummation of the Change of Control, state that the offer to purchase is conditioned on a Change of Control Repurchase Event occurring on or prior to the payment date specified in the notice. The Company shall
comply with the requirements of Rule 14e-1 under the Exchange Act, and any other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes as a result of a
Change of Control Repurchase Event. To the extent that the provisions of any securities laws or regulations conflict with the Change of Control Repurchase Event provisions of the Notes, the Company shall comply with the applicable securities laws
and regulations and shall not be deemed to have breached its obligations under the Change of Control Repurchase Event provisions of the Notes by virtue of such conflict. 
 On the repurchase date following a Change of Control Repurchase Event, the Company shall, to the extent lawful: 
  

	 	(i)	accept for payment all the Notes or portions of the Notes properly tendered pursuant to its offer; 

  
 10 

	 	(ii)	deposit with the Paying Agent an amount equal to the aggregate purchase price in respect of all of the Notes or portions of the Notes properly tendered; and

  

	 	(iii)	deliver or cause to be delivered to the Trustee the Notes properly accepted, together with an officer’s certificate stating the aggregate principal amount of Notes
being purchased by the Company. 

 The Paying Agent shall promptly mail to each Holder of Notes properly tendered,
the purchase price for the Notes, and the Trustee shall promptly authenticate and mail (or cause to be transferred by book-entry) to each Holder a new Note equal in principal amount to any unpurchased portion of any Notes surrendered. 

The Company shall not be required to make an offer to repurchase the Notes upon a Change of Control Repurchase Event if a third party
makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by the Company and such third party purchases all Notes properly tendered and not withdrawn under its offer. 

For purposes of this Section 4.02, the following definitions are applicable: 

“Change of Control” shall occur if: (1) any “person” (as such term is used in
Sections 13(d) and 14(d) of the Exchange Act) is or becomes the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act, except that for purposes of this clause (1) such person shall be deemed to have
“beneficial ownership” of all shares that any such person has the right to acquire, whether such right is exercisable immediately or only after the passage of time), directly or indirectly, of more than 50% of the total voting power of the
Voting Stock of the Company; (2) individuals who on the issue date of the Notes constituted the Board of Directors (together with any new directors whose election by such Board of Directors or whose nomination for election by the shareholders
of the Company was approved by a vote of
66 2/3% of the directors of the Company then still in office who were either directors on the issue date of the Notes or whose election or nomination for election was previously so approved) cease for any
reason to constitute a majority of the Board of Directors then in office; (3) the adoption of a plan relating to the liquidation or dissolution of the Company; or (4) the merger or consolidation of the Company with or into another person
or the merger of another person with or into the Company, or the sale of all or substantially all the assets of the Company (determined on a consolidated basis) to another person, other than a merger or consolidation transaction in which Holders of
securities that represented 100% of the Voting Stock of the Company immediately prior to such transaction (or other securities into which such securities are converted as part of such merger or consolidation transaction) own directly or indirectly
at least a majority of the voting power of the Voting Stock of the surviving person in such merger or consolidation transaction immediately after such transaction and in substantially the same proportion as before the transaction. 

“Change of Control Repurchase Event” means the occurrence of both a Change of Control and a Ratings Event. 

“Investment Grade” means a rating of Baa3 or better by Moody’s (or its equivalent under any successor Rating
Categories of Moody’s), a rating of BBB- or better by S&P (or its equivalent under any successor Rating Categories of S&P) and the equivalent Investment Grade credit rating from any additional Rating Agency or Rating Agencies selected
by the Company. 

  
 11 

 “Moody’s” means Moody’s Investors Service Inc. 

“Rating Agency” means (1) each of Moody’s and S&P and (2) if either of Moody’s or S&P ceases
to rate the Notes or fails to make a rating of the Notes publicly available for reasons outside of the control of the Company, a “nationally recognized statistical rating organization” within the meaning of Section 3(a)(62) under the
Exchange Act, selected by the Company (as certified by a resolution of the board of directors of the Company) as a replacement agency for Moody’s or S&P, or both, as the case may be. 

“Rating Category” means (1) with respect to S&P, any of the following categories: BBB, BB, B, CCC, CC, C and D
(or equivalent successor categories); (2) with respect to Moody’s, any of the following categories: Baa, Ba, B, Caa, Ca, C and D (or equivalent successor categories); and (3) the equivalent of any such category of S&P or
Moody’s used by another Rating Agency. In determining whether the rating of the Notes has decreased by one or more gradations, gradations within Rating Categories (+ and - for S&P; 1, 2 and 3 for Moody’s; or the equivalent gradations
for another Rating Agency) shall be taken into account (e.g., with respect to S&P, a decline in a rating from BB+ to BB, as well as from BB- to B+, shall constitute a decrease of one gradation). 

“Rating Date” means the date that is 60 days prior to the earlier of (1) a Change of Control or (2) public
notice of the occurrence of a Change of Control or of the intention by the Company to effect a Change of Control. 

“Ratings Event” means the occurrence of the events described in (a) or (b) of this definition on, or within 60
days after the earlier of, (1) the occurrence of a Change of Control or (2) public notice of the occurrence of a Change of Control or the intention by the Company to effect a Change of Control (which period shall be extended so long as the
rating of the Notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies): (a) if the Notes are rated by both Rating Agencies on the Rating Date as Investment Grade, the rating of the Notes shall be
reduced so that the Notes are rated below Investment Grade by both Rating Agencies, or (b) if the Notes are rated below Investment Grade by at least one Rating Agency, the ratings of the Notes by both Rating Agencies shall be decreased by one
or more gradations (including gradations within Rating Categories, as well as between Rating Categories) and the Notes are then rated below Investment Grade by both Rating Agencies. 

Notwithstanding the foregoing, a Ratings Event otherwise arising by virtue of a particular reduction in rating shall not be deemed to
have occurred in respect of a particular Change of Control (and thus shall not be deemed a Ratings Event for purposes of the definition of Change of Control Repurchase Event hereunder) if the Rating Agencies making the reduction in rating to which
this definition would otherwise apply do not announce or publicly confirm or inform the Trustee in writing at its request that the reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or
in respect of, the applicable Change of Control (whether or not the applicable Change of Control shall have occurred at the time of the Ratings Event). 

  
 12 

 “S&P” means Standard & Poor’s, a division of The
McGraw-Hill Companies, Inc. 
 “Voting Stock” of any specified “person” (as that term is used in
Section 13(d)(3) of the Exchange Act) as of any date means the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. 

ARTICLE FIVE 
 EVENTS OF DEFAULT 
 Section 5.01. Additional Event of Default.

 In addition to the Events of Default set forth in Section 5.01 of the Base Indenture, the Notes shall also be subject to
the following Event of Default: 
  

	 	(i)	a failure by the Company to repurchase Notes of such series tendered for repurchase following the occurrence of a Change of Control Repurchase Event in conformity with
Section 4.02. 

 ARTICLE SIX 
 MISCELLANEOUS 
 Section 6.01. Form of Notes. 

The Notes and the Trustee’s Certificates of Authentication to be endorsed thereon are to be substantially in the form of Exhibit A,
which forms are hereby incorporated in and made a part of this Supplemental Indenture. 
 The terms and provisions contained in
the Notes shall constitute, and are hereby expressly made, a part of this Supplemental Indenture, and the Company and the Trustee, by their execution and delivery of this Supplemental Indenture, expressly agree to such terms and provisions and to be
bound thereby. 
 Section 6.02. Ratification of Base Indenture. 

The Base Indenture, as supplemented by this Supplemental Indenture, is in all respects ratified and confirmed. 

Section 6.03. Application of Supplemental Indenture. 

This Supplemental Indenture shall be deemed part of the Base Indenture in the manner and to the extent herein and therein provided.

 Section 6.04. Trust Indenture Act Controls. 

If any provision hereof limits, qualifies or conflicts with the duties imposed by Sections 310 through 317 of the Trust Indenture Act,
the imposed duties shall control. 

  
 13 

 Section 6.05. Conflict with Base Indenture. 

To the extent not expressly amended or modified by this Supplemental Indenture, the Base Indenture shall remain in full force and effect.
If any provision of this Supplemental Indenture relating to the Notes is inconsistent with any provision of the Base Indenture, the provision of this Supplemental Indenture shall control. 

Section 6.06. Governing Law. 
 THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 
 Section 6.07. Successors. 
 All agreements of the Company in
the Base Indenture, this Supplemental Indenture and the Notes shall bind its successors. All agreements of the Trustee in the Base Indenture and this Supplemental Indenture shall bind its successors. 

Section 6.08. Counterparts. 
 This instrument may be executed in any number of counterparts, each of which so executed shall be deemed to be an original, but all such counterparts shall together constitute but one and the same
instrument. 
 Section 6.09. Trustee Disclaimer. 

The Trustee makes no representation as to the validity or sufficiency of this Supplemental Indenture other than as to the validity of its
execution and delivery by the Trustee. The recitals and statements herein are deemed to be those of the Company and not the Trustee. 
 [Remainder of page intentionally left blank] 

  
 14 

 IN WITNESS WHEREOF, the parties to this Supplemental Indenture have caused it to be
duly executed as of the day and year first above written. 
  

			
	UNITED STATES STEEL CORPORATION
		
	By:	 	 /s/ John Quaid

	Name:	 	J. J. Quaid
	Title:	 	Vice President & Treasurer
	
	 THE BANK OF NEW YORK MELLON,
 as Trustee

		
	By:	 	 /s/ Francine Kincaid

	Name:	 	Francine Kincaid
	Title:	 	Vice President

 [Signature Page to Sixth Supplemental Indenture] 

 Exhibit A 

Form of Global Note Representing the Notes 

 THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE SUPPLEMENTAL INDENTURE TO THE
INDENTURE GOVERNING THIS NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE
REQUIRED PURSUANT TO ARTICLE III OF THE INDENTURE, (II) THIS GLOBAL NOTE MAY BE EXCHANGED PURSUANT TO SECTION 3.05 OF THE INDENTURE, (III) THIS GLOBAL NOTE MAY BE DELIVERED TO THE TRUSTEE FOR CANCELLATION PURSUANT TO SECTION 3.09 OF THE INDENTURE
AND (IV) THIS GLOBAL NOTE MAY BE TRANSFERRED TO A SUCCESSOR DEPOSITARY WITH THE PRIOR WRITTEN CONSENT OF THE COMPANY OR ANY SUCCESSOR THERETO. 
 UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AS DEFINED IN THE SUPPLEMENTAL INDENTURE TO THE INDENTURE GOVERNING THIS NOTE), TO THE COMPANY OR ANY SUCCESSOR THERETO OR
ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY (AND ANY PAYMENT IS
MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITARY), ANY TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER
HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 

  
 1 

 2 

 

 UNITED STATES STEEL CORPORATION 

 

			
	No. [—]	  	 Principal Amount $ [—]
 CUSIP NO. [—]
 ISIN NO. [—]

 6.875% Senior Notes due 2021 

UNITED STATES STEEL CORPORATION, a Delaware corporation, for value received, hereby promises to pay to CEDE & CO., or registered
assigns, the principal sum of [—] DOLLARS ($[—]) on April 1, 2021. 
 Interest Payment Dates: April 1 and October 1 
 Record Dates:
March 15 and September 15 
 Additional provisions of this Note are set forth on the other side of this Note.

  
 2 

 IN WITNESS WHEREOF, the Company has caused this Instrument to be duly executed. 

 

			
	UNITED STATES STEEL CORPORATION
		
	By:	 	  

		 	Name:
		 	Title:

 ATTEST: 
  

	
	  

	Assistant Secretary

 Dated: 

  
 3 

 4 

 

 TRUSTEE CERTIFICATE OF AUTHENTICATION 

This is one of the Notes of the series designated therein referred to in the within-mentioned Indenture. 

 

					
	THE BANK OF NEW YORK MELLON, as Trustee
			
		 	By:	 	  

 
  

			
		 	Authorized Signatory
		
	Dated:	 	

  
 4 

 (Reverse of Note) 

6.875% Senior Notes due 2021 
  

	 	1.	Interest. 

 United States
Steel Corporation, a Delaware corporation (the “Company” and the “Issuer”) promises to pay interest on the principal amount of this Note at the rate per annum set forth above. 

The Issuer shall pay accrued interest semiannually on each April 1 and October 1, commencing on October 1, 2013 or if any
such day is not a Business Day (as defined in the Indenture referred to below), on the next Business Day. 
  

	 	2.	Method of Payment. 

 The
Issuer shall pay the principal of (and premium, if any) and interest on the Notes (except defaulted interest) to the Persons who are the registered Holders at the close of business on the Record Date immediately preceding the Interest Payment Date
even if the Notes are cancelled, repurchased or redeemed after such Record Date, and on or before such Interest Payment Date. Holders must surrender Notes to the Paying Agent to collect principal payments. The Issuer shall pay principal and interest
in money of the United States that at the time of payment is legal tender for payment of public and private debts (“U.S. Legal Tender”). However, the Issuer may pay principal and interest by check payable in such U.S. Legal Tender.
The Company may deliver any such interest payment to the Paying Agent or to a Holder at the Holder’s registered address. 
  

	 	3.	Paying Agent and Registrar. 

 Initially, The Bank of New York Mellon will act as Paying Agent and Security Registrar. The Company shall notify each Holder of changes in the identity of the Security Registrar. The Company or any of its
domestically incorporated wholly-owned Subsidiaries may act as the Paying Agent. 
  

	 	4.	Indenture. 

 The Issuer
issued the Notes under an Indenture, dated as of May 21, 2007 (the “Base Indenture”), between the Issuer and The Bank of New York Mellon (as successor to The Bank of New York), a New York banking corporation (the
“Trustee”), as supplemented by a Sixth Supplemental Indenture, dated as of March 26, 2013, between the Issuer and The Bank of New York Mellon, a New York banking corporation, as Trustee (the “Supplemental
Indenture,” and together with the Base Indenture, the “Indenture”). The terms of the Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939 (15 U.S.
C. §§ 77aaa-77bbbb), as in effect on the date of the Indenture (the “TIA”). Capitalized terms used herein and not defined herein have the meanings ascribed thereto in the Indenture. The Notes are subject to all such
terms, and Holders are referred to the Indenture and the TIA for a statement of terms. 

  
 5 

 6 

 

 The Notes are senior and unsecured obligations of the Issuer. The Notes include the
initial Notes and any additional Notes actually issued. The initial Notes and any additional Notes actually issued are treated as a single class of securities under the Indenture. The Indenture imposes certain limitations on the incurrence of Liens
and certain sale and leaseback transactions with respect to Principal Property and limits the Company’s ability to consolidate, merge or transfer, all or substantially all of the Company’s assets. Each Holder, by accepting a Note, agrees
to be bound by all of the terms and provisions of the Indenture. Any conflict between this Note and the Indenture will be governed by the Indenture. 
  

	 	5.	Optional Redemption. 

 On
and after April 1, 2017, the Company may redeem the Notes, at its option, at any time in whole or from time to time in part, upon not less than 30 nor more than 60 days’ notice, at the redemption prices (expressed in percentages of
principal amount) listed below, plus accrued and unpaid interest on the Notes, if any, to, but excluding, the applicable redemption date, if redeemed during the twelve-month period beginning on April 1 of the years indicated below. 

 

					
	 Year
	  	Percentage	 
	 2017
	  	 	103.438	% 
	 2018
	  	 	101.719	% 
	 2019 and thereafter
	  	 	100.000	% 

 At any time prior to April 1, 2017, the Company may also redeem the Notes, at its option, at any
time in whole, or from time to time in part, at a price equal to the greater of: 
  

	 	(i)	100% of the principal amount of the Notes to be redeemed; or 

  

	 	(ii)	the sum of the present values of the redemption price of the Notes to be redeemed if they were redeemed on April 1, 2017 (as described in the prior paragraph) and
all required interest payments due on such Notes through April 1, 2017, exclusive of interest accrued to the date of redemption, discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day
months) at the applicable Treasury Yield plus 50 basis points, 

 plus accrued and unpaid interest, if any, to,
but excluding, the date of redemption. 
  

	 	6.	Notice of Redemption. 

The Notes called for redemption become due on the date fixed for redemption. Notices of redemption shall be mailed by first-class mail at
least 30 but not more than 60 days before the redemption date to each Holder to be redeemed at its registered address. The notice of redemption for the Notes shall state the amount to be redeemed. On and after the redemption date, interest shall
cease to accrue on any Notes that are redeemed. If less than all of the Notes are redeemed at any time, the Trustee shall select Notes on a pro rata basis or by any other method the Trustee deems fair and appropriate. 

  
 6 

 7 

 

	 	7.	Change of Control Repurchase Event. 

 If a Change of Control Repurchase Event occurs, unless the Company has exercised its right to redeem the Notes pursuant to the Indenture, the Company shall be required to make an offer to each Holder to
repurchase all or any part (in excess of $1,000 and in integral multiples of $1,000) of that Holder’s Notes at a repurchase price in cash equal to 101% of the aggregate principal amount of the Notes repurchased plus any accrued and unpaid
interest on the Notes repurchased to, but not including, the date of repurchase. Within 30 days following any Change of Control Repurchase Event or, at the option of the Company, prior to any Change of Control, but after the public announcement of
the Change of Control, the Company shall mail a notice to each Holder, with a copy to the Trustee, describing the transaction or transactions that constitute or may constitute the Change of Control Repurchase Event and offering to repurchase the
Notes on the payment date specified in the notice, which date shall be no earlier than 30 days and no later than 60 days from the date such notice is mailed. The notice shall, if mailed prior to the date of consummation of the Change of Control,
state that the offer to purchase is conditioned on a Change of Control Repurchase Event occurring on or prior to the payment date specified in the notice. The Company shall comply with the requirements of Rule 14e-1 under the Exchange Act, and any
other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes as a result of a Change of Control Repurchase Event. To the extent that the provisions of any
securities laws or regulations conflict with the Change of Control Repurchase Event provisions of the Notes, the Company shall comply with the applicable securities laws and regulations and shall not be deemed to have breached its obligations under
the Change of Control Repurchase Event provisions of the Notes by virtue of such conflict. 
 On the repurchase date following a
Change of Control Repurchase Event, the Company shall, to the extent lawful: 
 (i) accept for payment all the Notes or portions
of the Notes properly tendered pursuant to its offer; 
 (ii) deposit with the Paying Agent an amount equal to the aggregate
purchase price in respect of all of the Notes or portions of the Notes properly tendered; and 
 (iii) deliver or cause to be
delivered to the Trustee the Notes properly accepted, together with an officer’s certificate stating the aggregate principal amount of Notes being purchased by the Company. 

The Paying Agent shall promptly mail to each Holder of Notes properly tendered, the purchase price for the Notes, and the Trustee shall
promptly authenticate and mail (or cause to be transferred by book-entry) to each Holder a new Note equal in principal amount to any unpurchased portion of any Notes surrendered. 

The Company shall not be required to make an offer to repurchase the Notes upon a Change of Control Repurchase Event if a third party
makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by the Company and such third party purchases all Notes properly tendered and not withdrawn under its offer. 

  
 7 

 8 

 

	 	8.	Denominations; Transfer; Exchange. 

 The Notes are in registered form without coupons in denominations of $1,000 and integral multiples thereof. A Holder may register, transfer or exchange Notes in accordance with the Indenture. The Security
Registrar may require a Holder, among other things, to furnish appropriate endorsements or transfer documents and to pay any taxes and fees required by law or permitted by the Indenture. The Security Registrar need not register the transfer of or
exchange any Notes selected for redemption (except, in the case of a Note to be redeemed in part, the portion of the Note not to be redeemed) for a period beginning 15 business days before a selection of Notes to be redeemed and ending on the date
of such selection. 
  

	 	9.	Persons Deemed Owners. 

The registered holder of this Note shall be treated as the owner of it for all purposes. 

 

	 	10.	Unclaimed Money. 

 If
money for the payment of principal or interest remains unclaimed for two years after the date of payment of principal and interest, the Trustee or Paying Agent shall pay the money back to the Issuer without interest thereon upon written request by
the Issuer. After any such payment, Holders entitled to the money shall look only to the Issuer and not the Trustee for payment. 
  

	 	11.	Defeasance. 

 Subject to
certain conditions set forth in the Indenture, the Issuer at any time may terminate some or all of its obligations under the Notes and the Indenture if the Issuer deposits with the Trustee money or U.S. Government Obligations for the payment of
principal of and interest on the Notes to redemption or maturity, as the case may be. 
  

	 	12.	Amendment, Waiver. 

Subject to certain exceptions set forth in the Indenture, (i) the Indenture or the Notes may be amended with the written consent of
the Holders of a least a majority in principal amount at maturity of the outstanding Notes and (ii) any default or noncompliance with any provision may be waived with the written consent of the Holders of a majority in principal amount at
maturity of the outstanding Notes. Subject to certain exceptions set forth in the Indenture, without the consent of any Holder, the Issuer and the Trustee may amend the Indenture or the Notes to cure any ambiguity, omission, defect or inconsistency,
or to provide for uncertificated Notes in addition to or in place of certificated Notes, or to secure the Notes, or to add additional covenants of the Issuer or surrender rights and powers conferred on the Issuer, or to make any change that does not
materially and adversely affect the rights of any Holder. 
  

	 	13.	Defaults and Remedies. 

Under the Indenture, Events of Default include (i) a failure by the Company to repurchase Notes of such series tendered for
repurchase following the occurrence of a Change of Control Repurchase Event in conformity with Paragraph 7 hereto and Section 4.02 of the 

  
 8 

 9 

 

 
Supplemental Indenture, (ii) a default in any payment of interest on any Note when due, continued for 30 days, (iii) a default in the payment of principal of (or premium, if any) on any
Note when due at its Maturity, (iv) a default in the deposit of any sinking fund payment, when and as due by the terms of the Note and continuance of such default for a period of 30 days, (v) a default by the Company in the performance, or
breach, of any covenant or warranty contained in the Indenture for 90 days after notice, and (vi) certain events of bankruptcy, insolvency or reorganization of the Company. If an Event of Default occurs and is continuing, the Trustee or the
Holders of at least 25% in aggregate principal amount of the outstanding Notes may declare all the Notes to be due and payable immediately. 
 Holders may not enforce the Indenture or the Notes except as provided in the Indenture. The Trustee may refuse to enforce the Indenture or the Notes unless it receives reasonable indemnity or security.
Subject to certain limitations, Holders of a majority in principal amount of the Notes may direct the Trustee in its exercise of any trust or power. The Trustee may withhold from Holders notice of any continuing Default or Event of Default (except a
Default or Event of Default in payment of principal or interest) if it determines that withholding notice is not opposed to their interest. 
  

	 	14.	Trustee Dealings with the Issuer. 

 Subject to the terms of the TIA and the Indenture, the Trustee under the Indenture, in its individual or any other capacity, may become the owner or pledgee of Notes and may otherwise deal with and
collect obligations owed to it by the Issuer or its Affiliates and may otherwise deal with the Issuer or its Affiliates with the same rights it would have if it were not the Trustee. 

 

	 	15.	No Recourse Against Others. 

 No director, officer, employee, member, incorporator or stockholder of the Issuer shall have any liability for any obligations of the Issuer under the Notes or the Indenture or for any claim based on, in
respect of, or by reason of such obligations or their creation. Each Holder of Notes by accepting a Note waives and releases all such liability. This waiver and release are part of the consideration for issuance of the Notes. 

 

	 	16.	Authentication. 

 This
Note shall not be valid until an authorized signature of the Trustee (or an authenticating agent (acting on its behalf)) manually signs the certificate of authentication on the other side of this Note. 

 

	 	17.	Abbreviations. 

 Customary
abbreviations may be used in the name of a Holder or an assignee, such as: TEN COM (= tenants in common), TEN ENT (= tenants by the entireties), JT TEN (= joint tenants with right of survivorship and not as tenants in common), CUST (= Custodian),
and U/G/M/A (= Uniform Gifts to Minors Act). 

  
 9 

 10 

 

	 	18.	CUSIP Numbers. 

 Pursuant
to a recommendation promulgated by the Committee on Uniform Security Identification Procedures the Issuer has caused CUSIP numbers to be printed on the Notes and has directed the Trustee to use CUSIP numbers in notices of redemption as a convenience
to Holders. No representation is made as to the accuracy of such numbers either as printed on the Notes or as contained in any notice of redemption and reliance may be placed only on the other identification numbers placed thereon. 

 

	 	19.	Governing Law. 

 THIS NOTE
SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. 

  
 10 

 ASSIGNMENT FORM 

To assign this Note, fill in the form below and have your signature guaranteed: 
 I or we assign and transfer this Note to: 
  
  

 
  
  

 
 (Print or type name, address and
zip code and 
 social security or tax ID number of assignee) 
 and irrevocably appoint
                                         agent to
transfer this Note on the books of the Company. The agent may substitute another to act for him. 
  

									
	Dated:	 	  
	 		 	Signed:	 	  

		 		 		 		 	(Sign exactly as your name appears on the other side of this Note)

 

			
	Signature Guarantee:	 	  

 (Signature must be guaranteed by a participant in a recognized Signature Guarantee Medallion Program or other signature
guarantor program reasonably acceptable to the Trustee) 

 OPTION OF HOLDER TO ELECT PURCHASE 

If you want to elect to have this Note purchased by the Issuer pursuant to Section 4.02 of the Supplemental Indenture, check the
box   ̈ 
 If you want to elect to have only part of this Note
purchased by the Issuer pursuant to Section 4.02 of the Supplemental Indenture, state the amount you elect to have purchased (must be integral multiple of $1,000): 

 

									
		 		 		 	$            
					
	Dated:	 	  
	 		 	Your Signature:	 	  

		 		 		 	Sign exactly as your name appears on the face of this Note.

  

			
	Signature Guarantee:	 	  

	(Signature must be guaranteed by a participant in a recognized Signature Guarantee Medallion Program or other signature guarantor program reasonably acceptable to the
Trustee)

  
 2 

 SCHEDULE OF EXCHANGES OF INTERESTS IN THE GLOBAL NOTE 

The following increases or decreases in this Global Note have been made: 

 

									
	 Date of Exchange
	 	 Amount of

decrease in

Principal

Amount of

this Global

Note
	 	 Amount of

increase in

Principal

Amount of

this Global

Note
	 	 Principal

Amount of this
 Global Note
 following such

decrease or

increase
	 	 Signature of

authorized

officer of

Trustee or

Notes

Custodian

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]